ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

10:30AM-12:30PM: Abstract Number: 0241

Anti-Spike Antibodies in SARS-CoV-2-Vaccinated SLE Patients

Infection-related Rheumatic Disease Poster

10:30AM-12:30PM: Abstract Number: 0285

Anti-THSD7A Antibodies Are Not Broadly Associated with IgG4-Related Disease or IgG4-Related Membranous Nephropathy

Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30PM: Abstract Number: 0256

Anti-TNF Therapy as a Potential Risk of Leishmania Infections

Infection-related Rheumatic Disease Poster

10:30AM-12:30PM: Abstract Number: 0442

Anti-U1-RNP Related Pregnancy Loss in Systemic Lupus Erythematosus

Reproductive Issues in Rheumatic Disorders Poster

10:30AM-12:30PM: Abstract Number: 0732

Antineutrophil Cytoplasmic Antibodies and Associated Vasculitis According to Clinical Phenotypes: A Single-Center Retrospective Cohort Study

Vasculitis – ANCA-Associated Poster I

10:30AM-12:30PM: Abstract Number: 0510

Applying Machine Learning Tools for Personalized Healthcare: Predicting Responses to Biologics in Rheumatoid Patients Through Comorbidity and Blood Test Analysis

RA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0178

Are Participants in Gout Clinical Trials Representative of People with Gout in the General Population?

Healthcare Disparities in Rheumatology Poster I

10:30AM-12:30PM: Abstract Number: 0689

Arrhythmic Burden, Myocardial Markers, and Long-term Survival in Distinct Cardiac Magnetic Resonance Subsets of Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0034

Arthritogenic Subdoligranulum (S. Dido 7) Is Increased in Individuals At-Risk for and with Early RA and Decreases over Time During Development of Inflammatory Arthritis

RA – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 0525

Assess the Effect of Increasing the Dose of Folic Acid Supplementation in Patients of Rheumatoid Arthritis with Methotrexate Intolerance – A Randomised Controlled Trial

RA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0395

Assessment of Enthesitis by Pediatric Rheumatology Providers

Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0293

Assessment of Skin Cancer Risk in Autoimmune Diseases: A Multivariate Analysis Using a National Inpatient Database

Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30PM: Abstract Number: 0730

Assessment of the Quality of Life in a Single-center Cohort of Patients with ANCA-Associated Vasculitis on Targeted Therapy: Characterization of Global, Disease and Organ-specific Parameters Using Patient Reported Outcomes

Vasculitis – ANCA-Associated Poster I

10:30AM-12:30PM: Abstract Number: 0116

Assessment of Triple Antiphospholipid Antibody-positive Patients Based on Clinical and Laboratory Domains of 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria

Antiphospholipid Syndrome Poster

10:30AM-12:30PM: Abstract Number: 0560

Association Between a Self-Report Screening Tool for Sarcopenia (SARC-F) and Disease Activity, Muscle Strength and Muscle Power Measures, Patient-Reported Outcomes and Body Composition in Patients with Spondyloarthritides

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster I

«Previous Page
1
…
3
4
5
6
7
…
60
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].